GeneSoft Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GeneSoft Inc.
Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.
RayzeBio And Genentech Show Interest In Radiopharmaceuticals Continues To Grow
RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.
Finance Watch: Two Biopharma IPOs Bring US Total To 17
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
SK Bioscience Pulls EU Filing For COVID Jab As Regulators Shift Focus To XBB Vaccines
The European Medicines Agency’s CHMP was set to adopt opinions on SK Bioscience’s COVID-19 vaccine and Mycovia/Gedeon’s Vivjoa for vulvovaginal candidiasis during its September meeting, but both marketing authorization filings were voluntarily withdrawn.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice